Home / Categories / By country / America / North America / Canada / HCP - Canada
Click to view full size image
Click here for details on how to download this file to your desktop.

Bexsero

Where can you turn for help in preventing MENB?

Serogroup B has become the most common invasive meningococcal disease (IMD) serogroup to affect Canadians (2011).

Percentage of reported IMD cases by age and serogroup, Canada (2007-2011)

AMONG INFANTS <1 year of age
79%

AMONG CHILDREN 1-4 years of age
74%

AMONG ADOLESCENTS 15-19 years of age
66%

BEXSERO

The first and only vaccine indicated for active immunization against invasive meningococcal disease caused by serogroup B strains.

BEXSERO is indicated for active immunization of individuals from 2 months through 17 years old against invasive disease caused by N. meningitidis serogroup B strains.

NOVARTIS VACCINES

BEXSERO
Multicomponent Meningococcal B Vaccine (recombinant, adsorbed)

Be informed. Be immunized.


Other ads from this campaign

Brand: Bexsero
Country/Market: Canada, North America
Target: Healthcare Professional (HCP)
Tagline: Be informed. Be immunized.
Size/duration: Single-page
Publication/Aired:
CMAJ-JAMC - May 19, 2015


See more Bexsero ads here
Rate this file (No vote yet)
File information
Download:Available for logged-in users with full-size access enabled.
Filename:Bexsero_CMAJ-JAMC-May192015_dtcCanada_SP.jpg
Keywords:fd57SORu , 55715 , xjbQfRer , Single-page , healthcare category , hcpCanada , Canada , Healthcare Professional (HCP) , Print ad , English , CMAJMay1915 , Where can you turn for help in preventing MENB? , Bexsero , Bexsero brand , Meningococcal Group B Vaccine Novartis , Vaccines And Diagnostics , adsorbed , bacterial meningitis , component , Diagnostics , Inoculation , MenB , Meningitis B , Prevention , Prophylaxis , protective , rDNA , septicaemia , Vaccine , Vaccines
Filesize:6421 KiB
Date added:May 24, 2015
Dimensions:3684 x 5000 pixels
Displayed:67 times
URL:https://adpharm.net/displayimage.php?pid=55715
My Collection:Add to collection
About Subscriptions Contact us Twitter LinkedIn